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Abstract
Background: Liver cirrhosis is characterized by fibrosis and nodule formation in the liver, due to a chronic injury,
and subsequent alteration of the normal architecture of the liver. Even though there is a huge effort to elucidate
the possible etiologic factors of liver cirrhosis, a significant number of cases are cryptogenic, especially in Sub
Saharan Africa, where there is a high burden of aflatoxin exposure. Aflatoxins are known to cause hepatocellular
carcinoma, which share similar etiologic factors with liver cirrhosis. This study aimed to assess the association
between aflatoxin exposure and the risk of liver cirrhosis.
Methods: Relevant studies were identified through systematic searches conducted in Ovid MEDLINE, PubMed and
Google Scholar. Also, by searching the references of retrieved articles. The abstracts and full text were screened for
eligibility and the risk of bias was assessed for each study using Joanna Briggs Institute (JBI) critical appraisal
checklist for observational studies. The extracted data from included studies using Microsoft Excel were exported to
Stata software version 15.0 for analyses. The overall pooled estimation of outcomes was calculated using a random-
effects model of DerSimonian–Laird method at a 95% confidence level. The heterogeneity of studies was
determined using I2 statistics. The presence of publication bias between studies was evaluated using the Begg’s
and Egger’s tests and funnel plot. The protocol of this systematic review and meta-analysis was registered in the
Prospero database with reference number ID: CRD42019148481.
Results: A total of 5 studies published between the years 2005 and 2018 that met the pre-defined inclusion and
exclusion criteria were included. The meta-analysis showed that a significant increase in the risk of liver cirrhosis is
associated with aflatoxin exposure (unadjusted pooled odds ratio (OR) = 3.35, 95% CI: 2.74–4.10, p = 0.000; I2 =
88.3%, p = 0.000; adjusted OR = 2.5, 95% CI: 1.84–3.39, p = 0.000; I2 = 0%, p = 0.429).
Conclusions: The present meta-analysis suggests that aflatoxin exposure is associated with a higher risk of liver
cirrhosis.
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Background
Cirrhosis is characterized by fibrosis and nodule forma-
tion in the liver, secondary to a chronic injury, which
leads to alteration of the normal lobular organization of
the liver [1, 2]. Cirrhosis is currently the 11th most com-
mon cause of death globally and liver cancer is the 16th
leading cause of death; when combined, they account for
3.5% of all deaths worldwide [3]. Despite the tremendous
amount of progress in our understanding the etiology of
liver cirrhosis, many cases are cryptogenic, i.e. cirrhosis
of the liver of undetermined etiology [4]. This is true es-
pecially in Sub Saharan Africa, where hepatitis B virus
(HBV), hepatitis C virus (HCV) and alcohol consump-
tion are involved in 34, 17, and 18% of cases as etiologic
factors. However, in 31% of cases, the etiology is
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unknown, according to a recent global burden of disease
report [5].
On the other hand, cirrhosis and hepatocellular carcin-
oma (HCC) are known to share numerous common
etiologic factors, including chronic infection with HBV
and/or HCV, heavy alcohol consumption, and non-
alcoholic steatohepatitis/non-alcoholic fatty liver disease
[5, 6]. An additional etiologic factor for HCC is exposure
to aflatoxins (AFs) through the consumption of AF con-
taminated foods [7]. In this regard, Sub Saharan Africa is
an area with a diet particularly high in AFs [8–10].
Emerging evidence has indicated that AF exposure
may be involved in the pathogenesis of liver cirrhosis
[11, 12]. Though there is no clear causation between AF
and liver cirrhosis, the mutational activity of AF has
been considered to be the main factor of AF-induced
HCC [13]. As both AF exposure and liver cirrhosis are
the main risk factors of HCC, it remains unclear whether
AF also contributes to the earlier stage of HCC progres-
sion, i.e., liver cirrhosis. The objective of this systematic
review was to analyze existing research to test the hy-
pothesis that AFs cause liver cirrhosis by meta-analysis
approach.
Methods
Study protocol
The Preferred Reporting Items for Systematic Review
and Meta-analysis (PRISMA) guideline was used to
report the finding of this review [14]. This systematic
review and meta-analysis was conducted by following
the PRISMA Protocol [15]. The completed checklist
has been provided as supplementary material (Add-
itional file 1: Table S1). The study protocol is regis-
tered on PROSPERO with reference number ID:
CRD42019148481.
Inclusion/exclusion criteria
During the screening and assessment of full texts for eli-
gibility, there were predefined inclusion-exclusion cri-
teria to arrive at the final included papers. Observational
studies (Case-control or cohort studies) addressing AF
exposure as a risk factor for liver cirrhosis were in-
cluded. There were no restrictions on publication year,
but only studies that were written in English were con-
sidered for inclusion. Studies having irretrievable full
texts (after requesting full texts from the corresponding
authors via email and/or Research Gate account) or
studies with unrelated or insufficient outcome measures
or studies with outcomes of interest that are missing or
vague were excluded.
Data sources and search strategy
We performed an electronic literature search until De-
cember 31st, 2019, on Ovid MEDLINE and PubMed:
using the following keywords and indexing terms: ‘afla-
toxin’, ‘liver cirrhosis’, and ‘chronic liver disease’. Ad-
vanced Google Scholar search was also conducted to
identify other relevant published and unpublished works
including dissertations, institutional repositories, and
organizational manuals, among others. Boolean opera-
tors (AND, OR) and truncation were used when appro-
priate to increase the number of relevant findings.
Additionally, we searched (back-traced) reference lists
from retrieved articles to identify further relevant
studies.
Screening and eligibility of studies
The documents identified from different electronic
sources were exported to ENDNOTE reference software
version 7.8 (Thomson Reuters, Stamford, CT, USA) with
compatible formats. Duplicate documents were removed
with the help of ENDNOTE and manually. Each of the
documents retrieved was assessed by the authors inde-
pendently for eligibility by reading the title, abstract
using the preset inclusion and exclusion criteria. This
process was followed by retrieval and assessment of the
full texts of the relevant citations. Any disagreement was
solved by discussion.
Data extraction
Data extraction format prepared in Microsoft Excel was
developed to extract data from each included study. The
authors independently extracted the data related to
study characteristics and outcome measures: including
authors, publication year, study design and populations,
study location, study period, diagnostic method, number
of cases and controls, the age and sex of study subjects,
method of AF exposure assessment (dietary intake of AF
contaminated foods and biomarkers of AF exposure
[249ser TP53 mutation, AF-albumin adduct, AF-N7-
guanine adducts excreted in urine]), risk ratios (RRs)/
odds ratios (ORs) and their 95% CI with or without ad-
justment for confounding factors, and variables adjusted
for analysis, if any.
Critical appraisal of studies
To maintain methodological validity, before the inclu-
sion of the eligible articles they were assessed by two in-
dependent reviewers using the Joanna Briggs Institute
(JBI) critical appraisal checklist for case-control and co-
hort studies [16]. The assessment tool consisted of 10
questions about the quality of the study for which arti-
cles received values representing the extent to which
they met the following criteria: Yes, No, Unclear and
Not applicable. This critical appraisal was conducted to
assess the internal (systematic error) and external
(generalizability) validity of studies and to reduce the
risk of biases. The mean score of the two authors was
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taken for final decision and studies with a score greater
than or equal to five out of 10 were considered low risk
and included in the study.
Outcome measurements
Our primary outcome of interest in this meta-analysis
was the association between AF exposure and the risk of
liver cirrhosis. Subgroup analyses based on information
on the study design, geographic location and method of
exposure assessment were performed.
Data processing and statistical analysis
The extracted data were exported from Excel to
STATA 15.0 software for analyses of outcome mea-
sures and sub-grouping. Considering the variation in
true effect sizes across the population, Der-Simonian-
Laird’s random-effects model was applied for the
analysis at 95% confidence level. The significance of
heterogeneity of the studies was assessed using I2 sta-
tistics based on Cochran’s Q test, I2 returns and the
percent variation across studies. The presence of
publication bias was evaluated using the Begg’s and
Mazumdar’s correlation and Egger’s regression tests
and presented with funnel plots [17, 18]. A statistical
test with a p-value of less than 0.05 was deemed to
be significant.
Results
Search result
As shown in Fig. 1, the search identified 506 studies, of
which 67 studies were found to be duplicates. From the
439 remaining records, 424 were excluded after reading
their titles and abstracts. Full texts of 15 records were
read to assess their eligibility. Of these, 10 records were
further excluded because they did not satisfy the inclu-
sion criteria. The remaining 5 studies [12, 19–22] were
included in this systematic review and meta-analysis.
Study characteristics
Among the five studies that met the inclusion criteria,
four of them were case-control studies and one study
was a nested case-control study. They were conducted
in Gambia [19, 20], Taiwan [12], India [21], and China
[22] and involved 941 cases and 2, 281 controls. The in-
cluded studies were published between 2005 and 2018.
As shown in Table 1, the included studies employed AF-
Fig. 1 PRISMA flow chart describing the selection process
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albumin adduct level [12, 21, 22], 249ser TP53 mutation
[19–21] and groundnut consumption [19, 20] as
methods of AF exposure assessment in liver cirrhosis pa-
tients. As depicted in Table 1, three of the included
studies reported unadjusted and adjusted ORs and two
studies [21, 22] did not report the adjusted odds ratio.
Most studies were adjusted for factors such as age, gen-
der, cigarette smoking, and alcohol drinking; two studies
[19, 20] were also adjusted for recruitment site and date,
socioeconomic status, HBV, and HCV status.
AF exposure and risk of liver cirrhosis
After pooling, the five studies that reported the un-
adjusted OR suggested a significantly higher risk of liver
cirrhosis associated with AF exposure (OR = 3.35, 95%
CI: 2.74–4.10, p = 0.000). However, high evidence of het-
erogeneity (I2 = 88.3%, p = 0.000) was observed in the
pooled estimate (Fig. 2).
On the other hand, after pooling of the adjusted OR
estimates of individual studies, AF exposure was still as-
sociated with a higher risk of liver cirrhosis (OR = 2.5,
95% CI: 1.84–3.39, p = 0.000) and no evidence of hetero-
geneity (I2 = 0%, p = 0.429) was found in the pooled esti-
mate and subgroup analysis (Fig. 3).
Subgroup analyses
As shown in Table 2, subgroup analyses by study de-
sign, AF exposure assessment method and geograph-
ical region of study populations were performed to
identify the sources of heterogeneity in the unadjusted
OR estimates of individual studies. In the subgroup
analysis by study design, the pooled estimate of case-
control was 3.67 (95% CI: 2.93–4.59, p = 0.000; I2 =
89.4%, p = 0.000). In the subgroup analysis by AF ex-
posure assessment method, the pooled estimate re-
vealed that there was a significant association between
AF-albumin adduct and liver cirrhosis [4.89 (95% CI:
3.77–6.35, p = 0.000; I2 = 88.8%, p = 0.000)], as well
as between 249ser TP53 mutation and liver cirrhosis
[4.30 (95% CI: 2.55–7.26, p = 0.000; I2 = 0.00%,
p = 0.863)] though no statistically significant associ-
ation was observed between groundnut consumption
and liver cirrhosis [1.15 (95% CI: 0.76–1.72, p = 0.51;
I2 = 82.4%, p = 0.017)].
In the subgroup analysis performed by geographical
region, the corresponding pooled OR for Asia was 4.85
(95% CI: 3.75–6.26, p = 0.000; I2 = 83.3%, p = 0.000), and
that of the African region was 1.84 (95% CI: 1.32–2.55,
p = 0.000; I2 = 85.5%, p = 0.000) (Table 2).
Publication bias
The presence of publication bias was depicted using fun-
nel plots of log OR and standard error of it and supple-
mented with statistical tests: Egger’s regression test
(p = 0.683 for unadjusted ORs and p = 0.122 for adjusted
ORs) and Begg’s and Mazumdar’s correlation test (con-
tinuity corrected) (p = 1.00 for unadjusted OR and
p = 0.22 for adjusted OR) (Fig. 4). The finding indicated
that there is no evidence of statistically significant publi-
cation bias among the included studies.
Discussion
This study is the first systematic review and meta-
analysis to investigate the relationship between exposure
Fig. 2 Forest plot of aflatoxin exposure and risk of liver cirrhosis using unadjusted odds ratios
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to AF and the risk of liver cirrhosis. The results of the
present study showed a significant association between
AF exposure and the risk of liver cirrhosis. Despite the
heterogeneity presented for most studies, those studies
that performed the adjusted tests were able to demon-
strate homogeneity in the comparisons. Subgroup ana-
lysis was conducted to reduce the degree of
heterogeneity among studies. The random effect model
has also been applied considering the variability of the
effect size.
A likely explanation of this association is not yet iden-
tified, though consumption of AF-contaminated foods
and feeds were reported to cause diverse degrees of liver
injury comprising development of fatty cysts, fibrosis,
and cirrhosis among humans and animals [23–27]. How-
ever, several lines of evidence support oxidative stress as
a key factor in AF induced initiation and progression of
liver cirrhosis [28–31].
The toxic effects of AFB1 against the liver and other or-
gans are closely related to its metabolic activation into the
free radical AFB1-exo-8,9-epoxide (AFBO) by cytochrome
P450 (CYP450) enzymes [32] and associated formation of
reactive oxygen species (ROS) including hydroxyl radical
(HO.), per hydroxyl radical (HOO−) and superoxide anion
[29, 33]. This can result in oxidative stress owing to an im-
balance between limited antioxidant defenses and the
Fig. 3 Forest plot of aflatoxin exposure and risk of liver cirrhosis using adjusted odds ratios
Table 2 Subgroup analyses of AF exposure and risk of liver cirrhosis using unadjusted ORs
Subgroup Studies,
N
OR (95% CI) p
value
Tests for heterogeneity
Q p I2
All studies 8 3.35 (2.74,4.10) 0.000 59.58 0.000 88.3%
Study design
Case-control studies 7 3.67 (2.93,4.59) 0.000 56.38 0.000 89.4%
Nested case-control studies 1 2.29 (1.44,3.64) 0.000 0.00 – –
Method of AF exposure assessment
Serum AF-albumin adduct level 3 4.89 (3.77, 6.35) 0.000 17.83 0.000 88.8%
249ser TP53mutation 3 4.3 (2.55,7.26) 0.000 0.30 0.863 0.0%
Groundnut consumption 2 1.15 (0.76,1.72) 0.51 5.68 0.017 82.4%
Geographic location
Asia 4 4.85 (3.75,6.26) 0.000 18.01 0.000 83.3%
Africa 4 1.84 (1.32,2.55) 0.000 20.75 0.000 85.5%
AF Aflatoxin, OR Odds ratio, CI Confidence interval
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excessive formation of ROS, resulting in the damage of bio-
logical molecules including lipids, proteins, and DNA in
cellular systems [34, 35]. In support of this hypothesis, sev-
eral studies have demonstrated the potential for antioxi-
dants to lower the risk of hepatotoxicity caused by
exposure to the AF [29, 36–39].
Moreover, many studies have reported the pivotal role of
oxidative stress induced by AF in eliciting programmed cell
death or apoptosis through mitochondrial signaling path-
ways [25, 40–42]. ROS induced mitochondrial damage is
known to cause uncoupling of mitochondrial oxidative
phosphorylation and the associated reduction in mitochon-
drial membrane potential following AFB1 administration
in vivo and in vitro [25, 33, 35]. Consequently, mitochon-
drial alterations cause activation of cytochrome C that
modulates Bcl2/Bax gene expression and activate caspase 9
and caspase 3, which results in cell death [41].
Conclusions
The current meta-analysis indicates that AF exposure is
significantly associated with liver cirrhosis. However,
large sample studies using standardized unbiased AF ex-
posure assessment methods and well-matched controls
are required to support this association further.
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